Publication:
Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.

dc.contributor.authorFlores-López, María
dc.contributor.authorGarcía-Marchena, Nuria
dc.contributor.authorAraos, Pedro
dc.contributor.authorRequena-Ocaña, Nerea
dc.contributor.authorPorras-Perales, Oscar
dc.contributor.authorTorres-Galván, Sandra
dc.contributor.authorSuarez, Juan
dc.contributor.authorPizarro, Nieves
dc.contributor.authorde la Torre, Rafael
dc.contributor.authorRubio, Gabriel
dc.contributor.authorRuiz-Ruiz, Juan Jesús
dc.contributor.authorRodríguez de Fonseca, Fernando
dc.contributor.authorSerrano, Antonia
dc.contributor.authorPavón-Morón, Francisco Javier
dc.date.accessioned2024-02-27T15:07:11Z
dc.date.available2024-02-27T15:07:11Z
dc.date.issued2022-04-30
dc.description.abstractPreclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in drug addiction. Recently, we reported alterations in the plasma concentrations of LPA species in patients with alcohol use disorder (AUD). As there are sex differences in drug addiction, the main aim of the present study was to investigate whether relevant LPA species (16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA) were associated with sex and/or substance use disorder (SUD). This exploratory study was conducted in 214 abstinent patients with lifetime SUD, and 91 healthy control subjects. The SUD group was divided according to the diagnosis of AUD and/or cocaine use disorder (CUD). Participants were clinically assessed, and plasma samples were collected to determine LPA species and total LPA. We found that LPA concentrations were significantly affected by sex, and women showed higher concentrations than men. In addition, there were significantly lower 16:0-LPA, 18:2-LPA and total LPA concentrations in patients with SUD than in controls. Namely, patients with CUD and AUD + CUD showed lower LPA concentrations than controls or patients with AUD. In conclusion, our data suggest that LPA species could be potential biomarkers for SUD in women and men, which could contribute to a better stratification of these patients in treatment programs.
dc.format.number5es_ES
dc.format.volume12es_ES
dc.identifier.doi10.3390/brainsci12050588
dc.identifier.issn2076-3425
dc.identifier.journalBrain scienceses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/20854
dc.identifier.pubmedID35624975es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18633
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectalcohol
dc.subjectbiomarker
dc.subjectcocaine
dc.subjectlysophosphatidic acid
dc.subjectsex
dc.subjectsubstance use disorder
dc.titleSex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files